Neuroprotective effects of umbelliferone and esculetin in a mouse model of Parkinson's disease

Journal of Neuroscience Research

Volumn 91, Issue 3, 2013, Pages 453-461

  Subramaniam, Sudhakar R ^a,b   Ellis, Elizabeth M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Coumarins; MPTP; Neuroprotection; Oxidative stress; Substantia nigra

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROTYROSINE; AMINE OXIDASE (FLAVIN CONTAINING); CASPASE 3; ESCULETIN; GLUTATHIONE; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; UMBELLIFERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA PARS COMPACTA;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; UMBELLIFERONES;

EID: 84872621264     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23164     Document Type: Article

References (56)

1. Barber SC, Higginbottom A, Mead RJ, Barber S, Shaw PJ.2009.An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic Biol Med 46:1127-1138.
2. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS.1978.Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38:3751-3757.
3. Bové J, Prou D, Perier C, Przedborski S.2005.Toxin-induced models of Parkinson's disease. NeuroRx 2:484-494.
4. Bradford MM.1976.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Chang WS, Chiang HC.1995.Structure-activity relationship of coumarins in xanthine oxidase inhibition. Anticancer Res 15:1969-1973.
6. Chang WS, Lin CC, Chuang SC, Chiang HC.1996.Superoxide anion scavenging effect of coumarins. Am J Chin Med 24:11-17.
7. Chen XC, Zhou YC, Chen Y, Zhu YG, Fang F, Chen LM.2005.Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin 26:56-62.
8. Chinta SJ, Andersen JK.2011.Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. Free Radic Res 45:53-58.
9. Cleren C, Yang L, Lorenzo B, Calingasan NY, Schomer A, Sireci A, Wille EJ, Beal MF.2008.Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem 104:1613-1621.
10. Crawford DR, Davies KJ.1994.Adaptive response and oxidative stress. Environ Health Perspect 102(Suppl 10):25-28.
11. Dauer W, Przedborski S.2003.Parkinson's disease: mechanisms and models. Neuron 39:889-909.
12. Davies KJ.1999.The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life 48:41-47.
13. de Vries HE, Witte M, Hondius D, Rozemuller AJ, Drukarch B, Hoozemans J, van Horssen J.2008.Nrf2-induced antioxidant protection: a promising target to counteract ROS-mediated damage in neurodegenerative disease?Free Radic Biol Med 45:1375-1383.
14. Dietz GP, Stockhausen KV, Dietz B, Falkenburger BH, Valbuena P, Opazo F, Lingor P, Meuer K, Weishaupt JH, Schulz JB, Bahr M.2008.Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. J Neurochem 104:757-765.
15. Ebadi M, Sharma S, Shavali S, El Refaey H.2002.Neuroprotective actions of selegiline. J Neurosci Res 67:285-289.
16. Ellis EM, Judah DJ, Neal GE, Hayes JD.1993.An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases. Proc Natl Acad Sci U S A 90:10350-10354.
17. Ellis EM, Judah DJ, Neal GE, Oconnor T, Hayes JD.1996.Regulation of carbonyl-reducing enzymes in rat liver by chemoprotectors. Cancer Res 56:2758-2766.
18. Ferger B, Spratt C, Teismann P, Seitz G, Kuschinsky K.1998.Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 360:155-163.
19. Galán A, García-Bermejo L, Troyano A, Vilaboa NE, Fernández C, de Blas E, Aller P.2001.The role of intracellular oxidation in death induction (apoptosis and necrosis) in human promonocytic cells treated with stress inducers (cadmium, heat, X-rays). Eur J Cell Biol 80:312-320.
20. Halliwell B.2001.Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18:685-716.
21. Hayes JD, Ellis EM, Neal GE, Harrison DJ, Manson MM.1999. Cellular response to cancer chemopreventive agents: contribution of the antioxidant responsive element to the adaptive response to oxidative and chemical stress. Biochem Soc Symp 64:141-168.
22. Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S.1995.Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Neurodegeneration 4:257-269.
23. Jenner P.1993.Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand Suppl 146:6-13.
24. Jeong SH, Han XH, Hong SS, Hwang JS, Hwang JH, Lee D, Lee MK, Ro JS, Hwang BY.2006.Monoamine oxidase inhibitory coumarins from the aerial parts of Dictamnus albus. Arch Pharm Res 29:1119-1124.
25. Kaneko T, Tahara S, Takabayashi F.2003.Suppression of lipid hydroperoxide-induced oxidative damage to cellular DNA by esculetin. Biol Pharm Bull 26:840-844.
26. Kaneko T, Tahara S, Takabayashi F.2007.Inhibitory effect of natural coumarin compounds, esculetin and esculin, on oxidative DNA damage and formation of aberrant crypt foci and tumors induced by 1, 2-dimethylhydrazine in rat colons. Biol Pharm Bull 30:2052-2057.
27. Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T.2007.Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J Pharmacol Exp Ther 322:274-281.
28. Kelly VP, Ellis EM, Manson MM, Chanas SA, Moffat GJ, McLeod R, Judah DJ, Neal GE, Hayes JD.2000.Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver. Cancer Res 60:957-969.
29. Kim SH, Kang KA, Zhang R, Piao MJ, Ko DO, Wang ZH, Chae SW, Kang SS, Lee KH, Kang HK, Kang HW, Hyun JW.2008.Protective effect of esculetin against oxidative stress-induced cell damage via scavenging reactive oxygen species. Acta Pharmacol Sin 29:1319-1326.
30. Laemmli UK.1970.Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
31. Levy OA, Malagelada C, Greene LA.2009. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis 14:478-500.
32. Li D, Ellis EM. 2012. Inducible protection of human astrocytoma 1321N1 cells against hydrogen peroxide and aldehyde toxicity by 7-hydroxycoumarin is associated with the upregulation of aldo-keto reductases. Neurotoxicology 33:1368-1374.
33. Li Y, Jaiswal AK.1994.Human antioxidant-response-element-mediated regulation of type 1 NAD(P)H:quinone oxidoreductase gene expression. Effect of sulfhydryl modifying agents. Eur J Biochem 226:31-39.
34. Martin HL, Teismann P.2009.Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23:3263-3272.
35. Mohanakumar KP, Muralikrishnan D, Thomas B.2000.Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity. Brain Res 864:281-290.
36. Muralikrishnan D, Mohanakumar KP.1998.Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912.
37. Parmar C, Kaushal MK.1982.Aegle marmelos. Wild fruits. New Delhi:Kalyani Publishers.
38. Paya M, Halliwell B, Hoult JR.1992.Peroxyl radical scavenging by a series of coumarins. Free Radic Res Commun 17:293-298.
39. Perry TL, Godin DV, Hansen S.1982.Parkinson's disease: a disorder due to nigral glutathione deficiency?Neurosci Lett 33:305-310.
40. Ramesh B, Pugalendi KV.2005.Impact of umbelliferone on erythrocyte redox status in STZ-diabetic rats. Yale J Biol Med 78:133-140.
41. Schafer FQ, Buettner GR.2001.Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191-1212.
42. Sollai F, Zucca P, Sanjust E, Steri D, Rescigno A.2008.Umbelliferone and esculetin: inhibitors or substrates for polyphenol oxidases?Biol Pharm Bull 31:2187-2193.
43. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M.1997.Alpha-synuclein in Lewy bodies. Nature 388:839-840.
44. Subramaniam SR, Ellis EM.2010.Esculetin-induced protection of human hepatoma HepG2 cells against hydrogen peroxide is associated with the Nrf2-dependent induction of the NAD(P)H: quinone oxidoreductase 1 gene. Toxicol Appl Pharmacol 250:130-136.
45. Sundt TMJr, Anderson RE.1980.Umbelliferone as an intracellular pH-sensitive fluorescent indicator and blood-brain barrier probe: instrumentation, calibration, and analysis. J Neurophysiol 44:60-75.
46. Tatton NA, Kish SJ.1997.In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048.
47. Thomas B.2009.Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 11:2077-2082.
48. van Muiswinkel FL, Kuiperij HB.2005.The Nrf2-ARE Signalling pathway: promising drug target to combat oxidative stress in neurodegenerative disorders. Curr Drug Targets CNS Neurol Disord 4:267-281.
49. Vila M, Jackson-Lewis V, Vukosavic S, Djaldetti R, Liberatore G, Offen D, Korsmeyer SJ, Przedborski S.2001.Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 98:2837-2842.
50. Weber CA, Ernst ME.2006.Antioxidants, supplements, and Parkinson's disease. Ann Pharmacother 40:935-938.
51. Weissbach H, Smith TE, Daly JW, Witkop B, Udenfriend S.1960.A rapid spectrophotometric assay of mono-amine oxidase based on the rate of disappearance of kynuramine J Biol Chem 235:1160-1163.
52. Wiese AG, Pacifici RE, Davies KJ.1995.Transient adaptation of oxidative stress in mammalian cells. Arch Biochem Biophys 318:231-240.
53. Wu FJ, Sheu SJ.1992.Analysis and processing of Chinese herbal drugs: The study of Fructus aurantti immaturus. Chin Pharm J 44:257-263.
54. Yong VW, Perry TL, Krisman AA.1986.Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci Lett 63:56-60.
55. Yue J-M, Xu J.1997.Chemical components from Ceratostigma willmottianum. J Nat Prod 60:1031-1033.
56. Zhou C, Huang Y, Przedborski S.2008.Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann N Y Acad Sci 1147:93-104.